What is the utility of quantifying Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM) in patients with acute renal failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Quantifying Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM) in patients with acute renal failure is crucial for identifying the underlying cause of renal impairment, particularly in cases where immune-mediated or paraproteinemic diseases like multiple myeloma are suspected. This is based on the most recent evidence from 2023, which highlights the importance of establishing the etiology of acute kidney injury (AKI) in patients with multiple myeloma 1. The measurements of these immunoglobulins can help diagnose conditions such as IgA nephropathy, membranous nephropathy, or multiple myeloma with cast nephropathy, which have distinct management strategies.

Key points to consider when interpreting these measurements include:

  • Normal reference ranges for IgG, IgA, and IgM, which typically are 700-1600 mg/dL, 70-400 mg/dL, and 40-230 mg/dL, respectively
  • Elevated IgA levels may indicate IgA nephropathy
  • Elevated IgG might suggest membranous nephropathy or lupus nephritis
  • Monoclonal elevations of any immunoglobulin class could indicate multiple myeloma with cast nephropathy These measurements should be interpreted alongside other diagnostic tests, including renal biopsy, serum and urine protein electrophoresis, complement levels, and autoimmune markers.

The utility of quantifying IgA, IgG, and IgM lies in their ability to guide treatment decisions, such as the use of ACE inhibitors and corticosteroids for IgA nephropathy, or urgent chemotherapy for multiple myeloma causing renal failure. By distinguishing between primary renal diseases and systemic conditions affecting the kidneys, immunoglobulin quantification plays a critical role in both immediate management and long-term treatment strategies for patients with acute renal failure.

From the Research

Utility of Quantifying Immunoglobulins in Acute Renal Failure

  • The utility of quantifying Immunoglobulin A (IgA), Immunoglobulin G (IgG), and Immunoglobulin M (IgM) in patients with acute renal failure is an area of interest due to the potential role of immunoglobulins in renal disease [(2,3,4,5,6)].

Immunoglobulin A (IgA) Nephropathy

  • IgA nephropathy is a known cause of acute kidney injury, with studies showing that patients with IgA nephropathy can present with acute kidney injury 3.
  • The presence of IgA deposits in the kidney can lead to inflammation and damage, resulting in acute renal failure 3.

Immunoglobulin Therapy and Acute Renal Failure

  • Intravenous immunoglobulin (IVIG) therapy has been associated with acute renal failure in some cases [(4,5,6)].
  • The exact mechanism of IVIG-induced renal failure is not fully understood, but it is thought to be related to the osmotic effects of the immunoglobulin preparations [(4,5,6)].

Quantification of Immunoglobulins

  • Quantifying IgA, IgG, and IgM levels may be useful in diagnosing and monitoring immunoglobulin-related renal diseases [(2,3)].
  • However, the utility of quantifying these immunoglobulins in acute renal failure is not well established, and further research is needed to determine their role in diagnosis and treatment [(2,3,4,5,6)].

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Acute renal failure associated with immunoglobulin therapy.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.